• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

West Pharma posts Street-beating Q3 earnings, sales

October 26, 2017 By Sarah Faulkner

WestShares in West Pharmaceutical Services (NYSE:WST) rose today after the company beat expectations on Wall Street with its third quarter results.

The Exton, Penn.-based company posted profits of $51 million, or 69¢ per share, on sales of $398.2 million for the 3 months ended Sept. 30, for bottom-line growth of 36% on sales growth of 6% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were 67¢, ahead of consensus on The Street, where analysts were looking for sales of $385.9 million.

“Our third-quarter performance was in line with our expectations,” president & CEO Eric Green said in prepared remarks.  “We are on track to finish 2017 with strong organic sales growth led by high-value product growth in the biologics and generics market units.

“Looking to the future, we continue to see positive fundamentals in the markets we serve.  We see unit volume growth from existing injectable drugs, future new drug approvals, and new generics and biosimilars that are entering the market.  There is continued growth potential for high-value product adoption in all our market units – pharma, generics and biologics – as customers strive for higher quality and increasingly adopt zero-defect strategic imperatives.  We have successfully focused our contract-manufactured product segment on serving injectable medicines and diagnostic customers, and our consumer goods business continues to become a smaller part of that segment’s sales.”

WST shares topped $100 apiece today for the first time this year, trading at $100.39 apiece in mid-morning activity, up 9.5%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: West Pharmaceutical Services

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS